LOng Term Effects of Cyclophosphamide Treatment on Lung Function and Survival in Scleroderma Patients with Interstitial Lung Disease

Open Rheumatology Journal

Volumn 5, Issue 1, 2011, Pages 1-6

  Mittoo, S ^a   Wigley, Fredrick M ^b   Wise, Robert A ^b   Woods, Adrianne ^b   Xiao, Huiqing ^b   Hummers, Laura K ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclophosphamide; Pulmonary fibrosis; Scleroderma

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ARTERY PRESSURE; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG LAVAGE; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCLERODERMA; TOTAL LUNG CAPACITY; TREATMENT DURATION;

EID: 80053545688     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901105010001     Document Type: Review

References (16)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66(7): 940-4.
2. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37(9): 1283-9.
3. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25): 2655-66.
4. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. Am J Respir Crit Care Med 2007.
5. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54(12): 3962-70.
6. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132(12): 947-54.
7. Kowal-Bielecka O, Kowal K, Rojewska J, et al. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 2005; 64(9): 1343-6.
8. Clements PJ, Goldin JG, Kleerup EC, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004; 50(6): 1909-17.
9. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23(5): 581-90.
10. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15(2): 202-5.
11. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159(1): 179-87.
12. Becklake MR, Goldman HI. The clinical uses of pulmonary function tests. S Afr Med J 1953; 27(1): 16-9.
13. Knudson RJ, Kaltenborn WT, Knudson DE, Burrows B. The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987; 135(4): 805-11.
14. Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29(11): 2371-8.
15. Yiannopoulos G, Pastromas V, Antonopoulos I, et al. Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007; 27(4): 357-61.
16. Airo P, Danieli E, Rossi M, et al. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 2007; 25(2): 293-6.